Detalhe da pesquisa
1.
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
J Neurol Neurosurg Psychiatry
; 95(5): 392-400, 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37963723
2.
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
Mult Scler
; 30(1): 44-54, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38018502
3.
Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol.
BMC Neurol
; 24(1): 28, 2024 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38225561
4.
Don't be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocol.
BMC Neurol
; 24(1): 26, 2024 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38218777
5.
A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage.
Brain
; 146(6): 2476-2488, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36535900
6.
The association between weight during early life and multiple sclerosis onset in a nationwide Dutch birth year cohort.
Nutr Neurosci
; 27(5): 499-505, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37409581
7.
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
J Neuroinflammation
; 20(1): 215, 2023 Sep 26.
Artigo
Inglês
| MEDLINE | ID: mdl-37752582
8.
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 482-486, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36639226
9.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(6): 487-493, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36693720
10.
Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis.
Mult Scler
; 29(4-5): 606-614, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36755463
11.
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
Mult Scler
; 29(8): 1001-1011, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36964707
12.
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Mult Scler
; 29(10): 1229-1239, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37530045
13.
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis.
Eur J Neurol
; 30(9): 2761-2768, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37306560
14.
Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.
Eur J Neurol
; 30(8): 2385-2392, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37170817
15.
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Mult Scler
; 28(4): 561-572, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34304609
16.
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
Mult Scler
; 28(8): 1286-1298, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34965774
17.
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Mult Scler
; 28(10): 1606-1619, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35876467
18.
Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
Mult Scler
; 28(11): 1808-1818, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35575214
19.
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
Mult Scler
; 28(14): 2231-2242, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36062492
20.
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
Mult Scler
; 28(1): 61-70, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33870779